MARKET WIRESeekingAlpha • 2d ago
Tango: Upgrading 'Buy' Based On ESMO 2026 Vopimetostat PDAC Data And Pathway Advancement ClarityWhy TNGX Stock advanced +1.35% Today — RQD Quant Desk Flash
$22.53 +1.35% NASDAQ • Public Delayed / 60s Snapshot
Tango Therapeutics Inc. (TNGX) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh money.
ROARABLE D+ • SELL / AVOID
Cap $3.80B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERSELL / AVOID • D+
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE-0.4% Base Target
WHALE OPTIONS TUG-OF-WAR:61% Call Buyers ($2.7M)
39% PutsMax Pain: $22.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TNGX Stock advanced +1.35% Today — RQD Quant Desk Flash
Tango Therapeutics Inc. (TNGX) advanced +1.35% to $22.53 as options desks priced 61% call premium vs. 39% put protection around the $22 max-pain magnet. Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 56% of its 52-week range ($7.37 – $34.39) with RSI-14 at 46.7 (NEUTRAL RANGE).
- ▸Whale Options Positioning: $2.7M in bullish call flow vs. $1.8M in put flow (Put/Call 0.65x, implied earnings swing ±6.5%).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 44% gross margin and $0 annual free cash flow.
Live TNGX Headlines & Catalysts
MARKET WIREBenzinga • 3d ago
HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price TargetHC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $68 price target.
MARKET WIREYahoo • 3d ago
Tango Therapeutics (TNGX) Following Trial Update Has Its Valuation Story Back In FocusTango Therapeutics (TNGX) has drawn fresh attention after reporting updated Phase 1/2 data for vopimetostat combined with RAS(ON) inhibitors in MTAP-deleted, RAS-mutant pancreatic and lung cancers, alongside plans for a
RISK WATCHSeekingAlpha • 3d ago
Tango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is SayingTango Therapeutics offers an 82% ORR and notable durability in MTAP-deleted/RAS-mutant pancreatic cancer. Read more on TNGX stock here.
MARKET WIREYahoo • 3d ago
Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside?Is TNGX a good stock to buy? We came across a bullish thesis on Tango Therapeutics, Inc. on BioEquity Watch’s Substack. Since the thesis was published on August 28th, TNGX shares have edged lower as investors weighed upd
MARKET WIRESeekingAlpha • 4d ago
Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer - SlideshowRISK WATCHYahoo • 5d ago
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study DataTango Therapeutics stock falls 16.4% despite an 82% pancreatic cancer response rate and durable disease control, as investors weigh updated results and R&D cuts.
CATALYSTYahoo • 8d ago
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer DrugTango Therapeutics beat expectations Friday for its combination using Revolution Medicines' newly approved drug in pancreatic cancer.
MARKET WIREYahoo • 8d ago
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response RateTango Therapeutics (NASDAQ:TNGX) said it plans to begin a global Phase III trial in the first half of 2027 evaluating vopimetostat in combination with daraxonrasib as a first-line treatment for patients with MTAP-deleted
MARKET WIREYahoo • 8d ago
Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?Tango Therapeutics Inc. (NASDAQ:TNGX) on Friday shared Phase 1/2 trial data for its investigational drug vopimetostat, revealing strong efficacy in treating advanced pancreatic and lung cancers. The biotechnology firm re
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Forensic Quant Desk
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring TNGX)
- ✓Live walkthrough of TNGX's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
TNGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +5.09%📐 HORIZONTAL RANGE
2026-10-30O $22.11H $22.75L $21.71C $22.72VOL 5.28M
RES: $28.13SUP: $20.56SMA50: $23.60SMA200: $22.33
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TNGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
21.4%/yr Implied 5Y Growth
vs. +48.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on TNGX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TNGX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TNGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
TNGX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is TNGX stock moving today?
Why TNGX Stock advanced +1.35% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.